Introduction and Epidemiology of Peri-implantitis
Peri-implantitis represents one of the most significant complications in implant dentistry, affecting patient satisfaction and implant longevity. Defined as an inflammatory process characterized by loss of supporting bone around osseointegrated implants, peri-implantitis has become increasingly prevalent as the implant patient population expands globally. According to epidemiological studies, the prevalence of peri-implantitis ranges from 6% to 43% at the implant level and 13% to 56% at the patient level, depending on follow-up duration and diagnostic criteria employed (Derks et al., 2016).
The distinction between peri-mucositis and peri-implantitis is clinically critical. Peri-mucositis involves reversible inflammation limited to the mucosa surrounding the implant, while peri-implantitis represents progressive disease with alveolar bone loss exceeding 2 millimeters in the coronal direction beyond the marginal bone level during the first year following implant placement or subsequent annual bone loss exceeding 0.8 millimeters. Understanding this classification enables clinicians to intervene at earlier disease stages, potentially preventing irreversible bone loss and implant loss.
Pathogenesis and Implant Surface Contamination
The etiopathogenesis of peri-implantitis involves complex interactions between microbial biofilm, host immune response, and implant surface characteristics. Unlike natural teeth, implants lack a periodontal ligament and possess a direct bone-to-implant contact (osseointegration), creating a fundamentally different anatomical environment for disease development. The peri-implant mucosa is thinner, less keratinized, and possesses fewer immune cells compared to periodontal tissues, rendering it more susceptible to pathogenic colonization.
Implant surface contamination initiates pathogenic biofilm formation. The topography of implant surfaces—including titanium, zirconia, or hybrid compositions—significantly influences bacterial adhesion. Rougher surfaces with greater surface area (Sa values of 1.5-2.5 micrometers) promote enhanced osseointegration during initial healing but simultaneously provide increased surface area for pathogenic biofilm colonization during disease states. Mombelli and Décaillet demonstrated that peri-implantitis biofilms contain more diverse microbial communities compared to healthy implant sites, with gram-negative anaerobic bacteria predominating, particularly Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia.
Surface contamination during manufacturing, implant placement, or prior to abutment connection creates microbial harboring sites. Corrosion products and titanium particles generated from implant surfaces can trigger inflammatory responses. Additionally, gap formation between implant components and abutments (sometimes exceeding 10 micrometers in platform-switched designs versus 40 micrometers in non-matched interfaces) creates micromotion and microbial leakage pathways that perpetuate chronic inflammation.
Bone Loss Patterns and Diagnostic Criteria
The radiographic pattern of bone loss in peri-implantitis typically progresses from the buccal or lingual plates, often resulting in characteristic "funnel-shaped" defects visible on radiographs. Three-dimensional computed tomography imaging reveals intraosseous defects with crater morphology, often demonstrating circumferential bone loss patterns more destructive than initial radiographic assessment suggests. Studies using cone-beam computed tomography document that peri-implantitis frequently involves bone loss exceeding 3-4 millimeters in depth within 1-2 years of disease initiation if untreated.
Clinical diagnostic indicators include probing depth measurements around implants exceeding 4 millimeters with positive bleeding on probing, suppuration, and patient-reported symptoms including discomfort or pain. Probing depth alone demonstrates poor specificity for peri-implantitis diagnosis in implants without prior bone loss, as healthy implants may demonstrate probing depths of 3-5 millimeters. Serial radiographic assessment at consistent angles and magnification becomes essential for documenting progressive alveolar bone loss, the definitive sign of disease progression.
Cumulative Interceptive Supportive Therapy (CIST)
Cumulative Interceptive Supportive Therapy represents a systematic non-surgical approach to peri-implantitis management, emphasizing early intervention and rigorous supportive care. The CIST protocol incorporates six critical components: patient education and oral hygiene reinforcement, mechanical removal of biofilm and inflammatory tissue, antimicrobial therapy when indicated, modulation of the host immune response, implant surface decontamination, and structured follow-up with appropriate recall intervals.
Initial mechanical therapy involves supragingival and subgingival debridement using ultrasonic instruments (particularly effective at 20-45 kilohertz frequencies) and specialized implant curettes. Titanium or plastic-tipped curettes prevent iatrogenic surface damage compared to steel instruments, which can create microgrooves promoting re-colonization. Subgingival irrigation with 0.12% chlorhexidine or 0.05% sodium hypochlorite solutions during debridement reduces bacterial load. Some practitioners employ photodynamic therapy using diode lasers (810-980 nanometers wavelength) with photosensitizing agents like methylene blue or indocyanine green, though evidence remains mixed regarding long-term clinical benefits.
Antimicrobial therapy in peri-implantitis management often includes local delivery agents and adjunctive systemic medications. Local chlorhexidine chips (releasing 2.5 milligrams over 7 days) or minocycline powder (2 milligrams per tooth) can be placed into peri-implant pockets. Systemic antibiotics, while less evidence-based than in periodontal disease, may be considered in aggressive cases: amoxicillin 500 milligrams three times daily plus metronidazole 500 milligrams three times daily for 7-10 days, or alternatively azithromycin 500 milligrams daily for 3 days. Heitz-Mayfield and Salvi recommend antimicrobial prescribing only when specific pathogens are identified through microbiological testing.
Regenerative Approaches and Tissue Engineering
Regenerative approaches aim to restore lost bone and peri-implant tissues, addressing the fundamental goal of disease management beyond simple biofilm suppression. Guided tissue regeneration (GTR) using barrier membranes has demonstrated variable success in peri-implantitis cases. Non-resorbable expanded polytetrafluoroethylene (ePTFE) membranes require secondary removal procedures but provide excellent mechanical barrier function for 4-6 weeks, critical for bone healing. Resorbable membranes including collagen (degrading over 2-3 weeks), polylactic acid, or polyglycolic acid-based materials avoid second surgeries but provide shorter barrier protection windows.
Bone regenerative materials combine mechanical space maintenance with biological activity. Autogenous bone harvested from intraoral sites (mentalis region, retromolar areas) provides optimal osteogenic potential with live osteoblasts and osteogenic proteins, achieving 40-50% peri-implant defect fill in clinical studies. Allografts (demineralized freeze-dried bone allograft or DFDBA, concentration 250-500 milligrams per site) provide osteoconductive scaffolding with diminished osteogenic potential compared to autogenous bone. Xenografts (bone mineral derived from bovine sources, frequently deproteinized) and alloplastic materials (bioactive glass, tricalcium phosphate) offer handling advantages with slower resorption profiles enabling prolonged space maintenance.
Growth factor therapy represents frontier regenerative technology in peri-implantitis management. Platelet-derived growth factor (PDGF, recombinant human PDGF-BB at concentrations of 0.3-1.5 milligrams/milliliter) has demonstrated superior outcomes in peri-implantitis defect healing compared to barrier membranes alone, stimulating angiogenesis and recruitment of progenitor cells. In comparative studies, PDGF with bone mineral enhanced bone regeneration in circumferential peri-implantitis defects by 30-45% compared to barrier membrane alone. Bone morphogenetic protein-2 (BMP-2) and BMP-7, though expensive ($1,500-3,000 per application) and demonstrating variable dosing protocols (0.43-1.5 milligrams/milliliter), promote osteoinductive bone formation through differentiation of mesenchymal stem cells into osteoblasts.
Surgical Debridement and Decontamination Techniques
Surgical access becomes necessary when non-surgical CIST management fails to arrest disease progression or when intraosseous defect morphology prevents adequate non-surgical instrumentation. Full-thickness flap elevation enables direct visualization and removal of granulation tissue, biofilm, and inflammatory soft tissue infiltrate. The flap design should preserve maximum keratinized tissue; apically repositioned flaps reduce peri-implant soft tissue volume but enable healing as secondary intention epithelialization.
Implant surface decontamination within surgical pockets employs mechanical and chemical modalities. Mechanical debridement using plastic curettes, titanium brushes (0.15 millimeter bristle diameter), or ultrasonic instruments removes loosely adherent biofilm. Chemical decontamination using 3% hydrogen peroxide irrigation, 0.12% chlorhexidine, or tetracycline hydrochloride solutions (50 milliliters of 50 micrograms/milliliter concentration) modulates remaining bacterial burden. Electrolytic cleaning (electrochemical decontamination using 24 volts direct current for 30-60 seconds) demonstrates experimental promise in laboratory studies but lacks substantial clinical evidence.
Air-abrasive systems delivering glycine powder (30 micrometers particles at 80 pounds per square inch) or sodium bicarbonate provide minimally invasive surface treatment without generating titanium particles or creating microgrooves. However, chlorhexidine jet polishing or hydroxyapatite-containing powders may provide superior antimicrobial activity compared to glycine alone.
Implant Removal Criteria and Salvage Assessment
Decision-making regarding implant removal versus salvage represents a critical clinical judgment point. Removal becomes indicated when clinical evidence documents continued disease progression despite adequate CIST and surgical management, specifically: progressive bone loss exceeding 2 millimeters annually during treatment, persistent suppuration and bleeding despite meticulous patient compliance, implant mobility (loss of osseointegration), or severe intraosseous defects exceeding 50% of implant length with crater morphology unsuitable for regeneration.
Patient factors influence removal decisions substantially. Immunocompromised patients (HIV/AIDS, uncontrolled diabetes with HbA1c exceeding 8%, chemotherapy recipients) demonstrate impaired peri-implantitis healing and higher disease recurrence rates, potentially favoring earlier removal. Poor oral hygiene compliance, smoking (particularly 20+ cigarettes daily), and active periodontitis at residual dentition predict inferior outcomes with salvage attempts.
Implant characteristics affect salvage feasibility. Short implants (≤8 millimeters length) with circumferential bone loss become increasingly difficult to retain due to reduced surface area for osseointegration recovery. Wide platform implants (≥5.0 millimeters diameter) frequently demonstrate more severe crater-form defects than narrow-body implants due to greater platform mismatch contributions. Severely contaminated implant surfaces or corrosion products resistant to decontamination may warrant removal to prevent chronic inflammation perpetuation.
Long-Term Outcomes and Supportive Maintenance
Following active peri-implantitis treatment (surgical or non-surgical), supportive maintenance care represents the critical phase determining clinical success. Evidence-based recall intervals remain controversial; some data suggests 3-month intervals for implants with prior peri-implantitis history, whereas others demonstrate adequate disease control with 6-month recalls in highly compliant patients. Risk stratification should guide individualized schedules: high-risk patients (smokers, poor hygiene, systemic disease, history of periodontitis) warrant 3-4 month recall intervals with enhanced professional cleaning and biofilm removal.
Long-term follow-up studies document that 50-70% of surgically treated peri-implantitis cases achieve disease arrest with meticulous supportive therapy, though complete bone fill of residual defects remains uncommon (10-20% of cases). Non-surgical CIST management demonstrates disease stabilization in 60-75% of cases when bone loss remains limited to ≤3 millimeters. Implant survival exceeds 95% at 5-year follow-up even in treated peri-implantitis cases, provided disease control is established and supportive therapy maintained.
Conclusion
Peri-implantitis management demands comprehensive understanding of disease pathogenesis, rigorous diagnostic protocols, and systematic treatment algorithms progressing from non-surgical CIST through surgical regenerative approaches when necessary. Early detection through serial radiographs and clinical assessment enables intervention during reversible stages, maximizing treatment outcomes and implant retention. Individualized maintenance protocols, reflecting patient-specific risk factors and disease history, remain essential for long-term implant stability and peri-implant health preservation.